News
AZ’s selumetinib for rare disease gets FDA breakthrough stat...
AstraZeneca and Merck & Co/MSD’s selumetinib has been given a breakthrough designation from the US FDA for a rare paediatric disease, after failing to make the grade in other cancers.
